Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma

References

• Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nature Reviews Cancer 2008; 8:967-75; PMID:18987634; http://dx.doi.org/10.1038/nrc2540
   PubMed Web of Science ®Google Scholar
• Bristow RG, Hill RP. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008; 8:180-92; PMID:18273037; http://dx.doi.org/10.1038/nrc2344
   PubMed Web of Science ®Google Scholar
• Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008; 8:851-64; PMID:18846101; http://dx.doi.org/10.1038/nrc2501
   PubMed Web of Science ®Google Scholar
• Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis 2009; 26:19-34; PMID:18543068; http://dx.doi.org/10.1007/s10585-008-9182-2
   PubMed Web of Science ®Google Scholar
• Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nature Reviews Cancer 2011; 11:393-410; PMID:21606941; http://dx.doi.org/10.1038/nrc3064
   PubMed Web of Science ®Google Scholar
• Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104. Clin Cancer Res 2007; 13:3922-32; PMID:17606726; http://dx.doi.org/10.1158/1078-0432.CCR-07-0478
   PubMed Web of Science ®Google Scholar
• Patel K, Lewiston D, Gu Y, Hicks KO, Wilson WR. Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 856:302-11; PMID:17644498; http://dx.doi.org/10.1016/j.jchromb.2007.06.035
   PubMed Web of Science ®Google Scholar
• Gu Y, Wilson WR. Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: Application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:3181-6; PMID:19709934; http://dx.doi.org/10.1016/j.jchromb.2009.08.009
   PubMed Web of Science ®Google Scholar
• Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, Wilson WR. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys 2007; 69:560-71; PMID:17869669; http://dx.doi.org/10.1016/j.ijrobp.2007.05.049
   PubMed Web of Science ®Google Scholar
• Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR. DNA crosslinks in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism and cytotoxicity. Cancer Res 2009; 69:3884-91; PMID:19366798; http://dx.doi.org/10.1158/0008-5472.CAN-08-4023
   PubMed Web of Science ®Google Scholar
• Gu Y, Patterson AV, Atwell GJ, Chernikova SB, Brown JM, Thompson LH, Wilson WR. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Molecular Cancer Therapeutics 2009; 8:1714-23; PMID:19509245; http://dx.doi.org/10.1158/1535-7163.MCT-08-1209
   PubMed Web of Science ®Google Scholar
• Guise CP, Abbattista MR, Tipparaju SR, Lambie NK, Su J, Li D, Wilson WR, Dachs GU, Patterson AV. Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia. Mol Pharmacol 2012; 81:31-40; PMID:21984255; http://dx.doi.org/10.1124/mol.111.073759
   PubMed Web of Science ®Google Scholar
• Guise CP, Wang A, Thiel A, Bridewell D, Wilson WR, Patterson AV. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 2007; 74:810-20; PMID:17645874; http://dx.doi.org/10.1016/j.bcp.2007.06.014
   PubMed Web of Science ®Google Scholar
• Guise CP, Abbattista M, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res 2010; 70:1573-84; PMID:20145130; http://dx.doi.org/10.1158/0008-5472.CAN-09-3237
   PubMed Web of Science ®Google Scholar
• Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22:1178-82; PMID:17559361; http://dx.doi.org/10.1111/j.1440-1746.2007.04997.x
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90; PMID:18650514; http://dx.doi.org/10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34; PMID:19095497; http://dx.doi.org/10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Crit Rev Oncol Hematol 2014; 91:1-8; PMID:24457121; http://dx.doi.org/10.1016/j.critrevonc.2013.12.013
   PubMed Web of Science ®Google Scholar
• Murakami M, Zhao S, Zhao Y, Chowdhury NF, Yu W, Nishijima KI, Takiguchi M, Tamaki N, Kuge Y. Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. Int J Oncol 2012; 41(5):1593-600; PMID:22965141; http://dx.doi.org/10.3892/ijo.2012.1624
   PubMed Web of Science ®Google Scholar
• Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59:561-74; PMID:17160391; http://dx.doi.org/10.1007/s00280-006-0393-4
   PubMed Web of Science ®Google Scholar
• Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, et al. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1alpha inhibition in hepatocellular carcinoma. Hepatology 2013; 57:1847-57; PMID:23299930; http://dx.doi.org/10.1002/hep.26224
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chan SL, Lin CC, Chiorean EG, Holcombe RF, Mulcahy MF, Carter WD, Patel K, Wilson WR, Melink TJ, et al. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2011; 68:539-45; PMID:21594722; http://dx.doi.org/10.1007/s00280-011-1671-3
   PubMed Web of Science ®Google Scholar
• Gu Y, Tingle MD, Wilson WR. Glucuronidation of anticancer prodrug PR-104A: Species differences, identification of human UDP-glucuronosyltransferases and implications for therapy. J Pharmacol Exp Ther 2011; 337:692-702; PMID:21427202; http://dx.doi.org/10.1124/jpet.111.180703
   PubMed Web of Science ®Google Scholar
• Gu Y, Atwell GJ, Wilson WR. Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs and humans. Drug Metab Dispos 2010; 38:498-508; PMID:20019245; http://dx.doi.org/10.1124/dmd.109.030973
   PubMed Web of Science ®Google Scholar
• MacLeod AK, McMahon M, Plummer SM, Higgins LG, Penning TM, Igarashi K, Hayes JD. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 2009; 30:1571-80; PMID:19608619; http://dx.doi.org/10.1093/carcin/bgp176
   PubMed Web of Science ®Google Scholar
• Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci U S A 1996; 93:14960-5; PMID:8962164; http://dx.doi.org/10.1073/pnas.93.25.14960
   PubMed Web of Science ®Google Scholar
• Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236:313-22; PMID:9240432; http://dx.doi.org/10.1006/bbrc.1997.6943
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66:11851-8; PMID:17178882; http://dx.doi.org/10.1158/0008-5472.CAN-06-1377
   PubMed Web of Science ®Google Scholar
• Liu LP, Ho RL, Chen GG, Lai PB. Sorafenib inhibits hypoxia-inducible factor-1alpha synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin Cancer Res 2012; 18:5662-71; PMID:22929805; http://dx.doi.org/10.1158/1078-0432.CCR-12-0552
   PubMed Web of Science ®Google Scholar
• Bryan HK, Olayanju A, Goldring CE, Park BK. The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol 2013; 85:705-17; PMID:23219527; http://dx.doi.org/10.1016/j.bcp.2012.11.016
   PubMed Web of Science ®Google Scholar
• Cullinan SB, Diehl JA. Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Bio 2006; 38:317-32; PMID:16290097; http://dx.doi.org/10.1016/j.biocel.2005.09.018
   PubMed Web of Science ®Google Scholar
• Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014; 346:1480-6; PMID:25394791; http://dx.doi.org/10.1126/science.1254721
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-109; PMID:15466206; http://dx.doi.org/10.1158/0008-5472.CAN-04-1443
   PubMed Web of Science ®Google Scholar
• Patel K, Choy SF, Hicks KO, Melink TJ, Holford NHG, Wilson WR. A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity. Cancer Chemother Pharmacol 2011; 67:1145-55; PMID:20683596; http://dx.doi.org/10.1007/s00280-010-1412-z
   PubMed Web of Science ®Google Scholar
• Konopleva M, Thall PF, Arana Yi C, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, et al. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid and acute lymphoblastic leukemia. Haematologica 2015; PMID:25682597; http://dx.doi.org/10.3324/haematol.2014.118455
   PubMed Web of Science ®Google Scholar
• Yang S, Atwell GJ, Denny WA. Synthesis of asymmetric halomesylate mustards with aziridineethanol/alkali metal halides: application to an improved synthesis of the hypoxia prodrug PR-104. Tetrahedron 2007; 63:5470-6; http://dx.doi.org/10.1016/j.tet.2007.04.044
   Web of Science ®Google Scholar
• Atwell GJ, Denny WA. Synthesis of 3H- and 2H4-labelled versions of the hypoxia-activated pre-prodrug 2-[(2-bromoethyl)-2,4-dinitro-6-[[[2-(phosphonooxy)ethyl]amino]carbonyl]anilino]ethyl methanesulfonate (PR-104). J Labelled Comp Radiopharm 2007; 50:7-12; http://dx.doi.org/10.1002/jlcr.1147
   Web of Science ®Google Scholar
• Yee DJ, Balsanek V, Bauman DR, Penning TM, Sames D. Fluorogenic metabolic probes for direct activity readout of redox enzymes: Selective measurement of human AKR1C2 in living cells. Proc Natl Acad Sci U S A 2006; 103:13304-9; PMID:16938874; http://dx.doi.org/10.1073/pnas.0604672103
   PubMed Web of Science ®Google Scholar
• Flanagan JU, Atwell GJ, Heinrich DM, Brooke DG, Silva S, Rigoreau LJ, Trivier E, Turnbull AP, Raynham T, Jamieson SM, et al. Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-b-hydroxysteroid dehydrogenase (AKR1C3). Bioorg Med Chem 2014; 22:967-77; PMID:24411201; http://dx.doi.org/10.1016/j.bmc.2013.12.050
   PubMed Web of Science ®Google Scholar
• Jamieson SM, Gu Y, Manesh DM, El-Hoss J, Jing D, MacKenzie KL, Guise CP, Foehrenbacher A, Pullen SM, Benito J, et al. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells. Biochem Pharmacol 2014; 88:36-45; PMID:24434189; http://dx.doi.org/10.1016/j.bcp.2013.12.019
   PubMed Web of Science ®Google Scholar
• Foehrenbacher A, Patel K, Abbattista M, Guise CP, Secomb TW, Wilson WR, Hicks KO. The role of bystander effects in the antitumor activity of the hypoxia-activated prodrug PR-104. Front Oncol 2013; 3:263; PMID:24109591
   PubMedGoogle Scholar
• Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006; 1:1112-6; PMID:17406391; http://dx.doi.org/10.1038/nprot.2006.179
   PubMed Web of Science ®Google Scholar
• Jamieson SM, Gu Y, Manesh DM, El-Hoss J, Jing D, MacKenzie KL, Guise CP, Foehrenbacher A, Pullen SM, Benito J, et al. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells. Biochem Pharmacol 2014; 88:36-45; PMID:24434189; http://dx.doi.org/10.1016/j.bcp.2013.12.019
   PubMed Web of Science ®Google Scholar
• Halim M, Yee DJ, Sames D. Imaging induction of cytoprotective enzymes in intact human cells: coumberone, a metabolic reporter for human AKR1C enzymes reveals activation by panaxytriol, an active component of red ginseng. J Am Chem Soc 2008; 130:14123-8; PMID:18826220; http://dx.doi.org/10.1021/ja801245y
   PubMed Web of Science ®Google Scholar